Infinite Coordination Polymer Polydopamine Nanocomposites Dual-Pathway Multistep Induction of Long-Term Hyperimmunity Combined With Photothermal-Chemo Synergistic Therapy Colorectal Cancer

Abstract

To improve the long-term therapeutic efficacy of colorectal cancer, we propose a synergistic treatment strategy involving dual-pathway, multistep induction of long-term hyperimmunity combined with photothermal-chemotherapy. To implement this strategy, infinite coordination polymer nanoparticles (SN38-Mn(II)-EGCG ICP NPs) were prepared by coordinating SN38, EGCG, and Mn²⁺. These nanoparticles were then coated with polydopamine (PDA) and grafted with folate-PEG-thiol (FA-PEG-SH) onto their surfaces, producing tumor-targeting folate-modified PDA infinite coordination polymer nanocomposites (ICP@FA-PDA nanocomposites). These nanocomposites exhibit a particle size of 94.9 ± 1.6 nm with a high drug loading capacity (83.3% ± 1.5%), drug release under acidic conditions while maintaining stability in physiological environments. Furthermore, each component within the nanocomposites serves multiple functions. Notably, the incorporation of multiple components triggers a powerful antitumor immune effect and establishes enduring immune memory through a dual-pathway and multistep approach, which is produced with the activation of the cGAS-STING pathway and immunogenic cell death (ICD) by a four-component multistep process. Under a low-dose regimen, this approach induces dual-pathway hyperimmunity effect and generates ultra-long immunological memory, marked by a ninefold increase in CD8⁺ T cell infiltration, a fourfold increase in CD4⁺ T lymphocytes, a fourfold reduction in Treg cells, and a fivefold increase in memory T cells. The remarkable therapy efficacy is achieved by hyperimmunity effect combination of SN38 and EGCG chemotherapy and photothermal therapy. In vivo studies demonstrated that mice treated with ICP@FA-PDA nanocomposites achieved complete eradication of cancer within 21 days, with no recurrence observed within 60 days. These nanocomposites hold significant promise and potential for future clinical translation.

Keywords

hyperimmunity / infinite coordination polymer / nanocomposites / synergistic therapy / ultra-long immunological memory

References

[1] R. L. Siegel, N. S. Wagle, A. Cercek, R. A. Smith, and A. Jemal, “Colorectal Cancer Statistics, 2023,” CA—A Cancer Journal for Clinicians 73 (2023): 233-254.

[2] N. Keum and E. Giovannucci, “Global Burden of Colorectal Cancer: Emerging Trends, Risk Factors and Prevention Strategies,” Nature Reviews Gastroenterology & Hepatology 16 (2019): 713-732.

[3] Y. Xie, Y. Chen, and J. Fang, “Comprehensive Review of Targeted Therapy for Colorectal Cancer,” Signal Transduction and Targeted Therapy 5 (2020): 22.

[4] V. Mulens-Arias, A. Nicolás-Boluda, A. Pinto, et al., “Tumor-Selective Immune-Active Mild Hyperthermia Associated With Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes,” American Chemical Society Nano 15 (2021): 3330-3348.

[5] S. Luo, Y. Wang, S. Shen, et al., “IR780-Loaded Hyaluronic Acid@Gossypol-Fe(III)-EGCG Infinite Coordination Polymer Nanoparticles for Highly Efficient Tumor Photothermal/Coordinated Dual Drugs Synergistic Therapy,” Advanced Functional Materials 31 (2021): 2100954.

[6] H. Zhu, C. Huang, J. Di, et al., “Doxorubicin-Fe(III)-Gossypol Infinite Coordination Polymer@PDA:CuO₂ Composite Nanoparticles for Cost-Effective Programmed Photothermal-Chemodynamic-Coordinated Dual Drug Chemotherapy Trimodal Synergistic Tumor Therapy,” American Chemical Society Nano 17 (2023): 12544-12562.

[7] D. An, J. Fu, B. Zhang, et al., “NIR-II Responsive Inorganic 2D Nanomaterials for Cancer Photothermal Therapy: Recent Advances and Future Challenges,” Advanced Functional Materials 31 (2021): 2101625.

[8] X. Li, J. F. Lovell, J. Yoon, and X. Chen, “Clinical Development and Potential of Photothermal and Photodynamic Therapies for Cancer,” Nature Reviews Clinical Oncology 17 (2020): 657-674.

[9] Q. Zhu, F. Sun, T. Li, et al., “Engineering Oxaliplatin Prodrug Nanoparticles for Second Near-Infrared Fluorescence Imaging-Guided Immunotherapy of Colorectal Cancer,” Small 17 (2021): e2007882.

[10] J. Chen, H. Gu, S. Fu, et al., “Multifunctional Injectable Hydrogels for Three-in-One Cancer Therapy: Preoperative Remission via Mild Photothermal-Enhanced Supramolecular Chemotherapy and Prevention of Postoperative Recurrence and Adhesion,” Chemical Engineering Journal 425 (2021): 130337.

[11] Q. Liu, Z. Xie, M. Qiu, et al., “Prodrug-Loaded Zirconium Carbide Nanosheets as a Novel Biophotonic Nanoplatform for Effective Treatment of Cancer,” Advancement of Science 7 (2020): 2001191.

[12] K. Okla, D. L. Farber, and W. Zou, “Tissue-Resident Memory T Cells in Tumor Immunity and Immunotherapy,” Journal of Experimental Medicine 218 (2021): e20201605.

[13] L. Qiao, G. Zhu, T. Jiang, et al., “Self-Destructive Copper Carriers Induce Pyroptosis and Cuproptosis for Efficient Tumor Immunotherapy Against Dormant and Recurrent Tumors,” Advanced Materials 36 (2024): 2308241.

[14] Z. Jin and F. A. Sinicrope, “Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade,” Journal of Clinical Oncology 40 (2022): 2735-2750.

[15] J. Galon and D. Bruni, “Approaches to Treat Immune Hot, Altered and Cold Tumours With Combination Immunotherapies,” Nature Reviews Drug Discovery 18 (2019): 197-218.

[16] C. Liu, X. Wang, W. Qin, et al., “Combining Radiation and the ATR Inhibitor Berzosertib Activates STING Signaling and Enhances Immunotherapy via Inhibiting SHP1 Function in Colorectal Cancer,” Cancer Communications 43 (2023): 435-454.

[17] L. Cao, H. Tian, M. Fang, et al., “Activating cGAS-Sting Pathway With ROS-Responsive Nanoparticles Delivering a Hybrid Prodrug for Enhanced Chemo-Immunotherapy,” Biomaterials 290 (2022): 121856.

[18] Q. Huang, X. Liu, H. Wang, et al., “A Nanotherapeutic Strategy to Overcome Chemoresistance to Irinotecan/7-Ethyl-10-Hydroxy-Camptothecin in Colorectal Cancer,” Acta Biomaterialia 137 (2022): 262-275.

[19] Z. Wang, W. Li, J. Park, K. M. Gonzalez, A. J. Scott, and J. Lu, “Camptothesome Elicits Immunogenic Cell Death to Boost Colorectal Cancer Immune Checkpoint Blockade,” Journal of Controlled Release 349 (2022): 929-939.

[20] Y. Wang, B. Wei, D. Wang, et al., “Author Correction to “DNA Damage Repair Promotion in Colonic Epithelial Cells by Andrographolide Downregulated cGAS‒STING Pathway Activation and Contributed to the Relief of CPT-11-Induced Intestinal Mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262-273],” Acta Pharmaceutica Sinica B 13 (2023): 3177.

[21] L. Wang, Y. Wu, T. Weng, et al., “Binding of Combined Irinotecan and Epicatechin to a pH-Responsive DNA Tetrahedron for Controlled Release and Enhanced Cytotoxicity,” Journal of Molecular Structure 1283 (2023): 135323.

[22] X. Sun, Y. Zhang, J. Li, et al., “Amplifying STING Activation by Cyclic Dinucleotide-Manganese Particles for Local and Systemic Cancer Metalloimmunotherapy,” Nature Nanotechnology 16 (2021): 1260-1270.

[23] J. Yan, G. Wang, L. Xie, et al., “Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate Sting Pathway Activation for Advanced Radiotherapy,” Advanced Materials 34 (2022): e2105783.

[24] W. Zeng, Z. Li, Q. Huang, et al., “Multifunctional Mesoporous Polydopamine-Based Systematic Delivery of STING Agonist for Enhanced Synergistic Photothermal-Immunotherapy,” Advanced Functional Materials 34 (2024): 2307241.

[25] B. Li, T. Gong, N. Xu, et al., “Improved Stability and Photothermal Performance of Polydopamine-Modified Fe₃O₄ Nanocomposites for Highly Efficient Magnetic Resonance Imaging-Guided Photothermal Therapy,” Small 16 (2020): 2003969.

[26] J. Yang, M. Hou, W. Sun, et al., “Sequential PDT and PTT Using Dual-Modal Single-Walled Carbon Nanohorns Synergistically Promote Systemic Immune Responses Against Tumor Metastasis and Relapse,” Advancement of Science 7 (2020): 2001088.

[27] Z. Li, Y. Yang, H. Wei, et al., “Charge-Reversal Biodegradable MSNs for Tumor Synergetic Chemo/Photothermal and Visualized Therapy,” Journal of Controlled Release 338 (2021): 719-730.

[28] F. Zhang, G. Lu, X. Wen, et al., “Magnetic Nanoparticles Coated With Polyphenols for Spatio-Temporally Controlled Cancer Photothermal/Immunotherapy,” Journal of Controlled Release 326 (2020): 131-139.

[29] A. Jin, Y. Wang, K. Lin, and L. Jiang, “Nanoparticles Modified by Polydopamine: Working as “Drug” Carriers,” Bioactive Materials 5 (2020): 522-541.

[30] Y. Li, L. Li, Y. Hao, et al., “Optimizing Structural Design in SN38 Delivery: More Assembly Stability and Activation Efficiency,” Nano Today 58 (2024): 102450.

[31] D. Wu, Y. Li, L. Zhu, et al., “A Biocompatible Superparamagnetic Chitosan-Based Nanoplatform Enabling Targeted SN-38 Delivery for Colorectal Cancer Therapy,” Carbohydrate Polymers 274 (2021): 118641.

[32] M. Zhang, X. Gao, Y. Su, et al., “Fabrication of Egg White Protein/Phosphatidylcholine-EGCG Co-Assembled Nanoparticles With Sustained Release in Simulated Gastrointestinal Digestion and Their Transcellular Permeability in Caco-2 Cultures,” Food Hydrocolloids 143 (2023): 108906.

[33] J. He, C. Li, L. Ding, et al., “Tumor Targeting Strategies of Smart Fluorescent Nanoparticles and Their Applications in Cancer Diagnosis and Treatment,” Advanced Materials 31 (2019): 1802409.

[34] Y. Liu, Y. Xu, Y. Wang, J. Lv, K. Wang, and Z. Tang, “Correction: Hindering the Unlimited Proliferation of Tumor Cells Synergizes With Destroying Tumor Blood Vessels for Effective Cancer Treatment,” Biomaterials Science 12 (2024): 2755-2756.

[35] Y. Wang, H. Xie, K. Ying, et al., “Tuning the Efficacy of Esterase-Activatable Prodrug Nanoparticles for the Treatment of Colorectal Malignancies,” Biomaterials 270 (2021): 120705.

[36] P. L. Collins, C. Purman, S. I. Porter, et al., “DNA Double-Strand Breaks Induce H2Ax Phosphorylation Domains in a Contact-Dependent Manner,” Nature Communications 11 (2020): 3158.

[37] M. Motwani, S. Pesiridis, and K. A. Fitzgerald, “DNA Sensing by the cGAS-STING Pathway in Health and Disease,” Nature Reviews Genetics 20 (2019): 657-674.

[38] T. Tsering, A. Nadeau, T. Wu, K. Dickinson, and J. V. Burnier, “Extracellular Vesicle-Associated DNA: Ten Years Since Its Discovery in Human Blood,” Cell Death & Disease 15 (2024): 668.

[39] C. Fang, F. Mo, L. Liu, et al., “Oxidized Mitochondrial DNA Sensing by STING Signaling Promotes the Antitumor Effect of an Irradiated Immunogenic Cancer Cell Vaccine,” Cellular & Molecular Immunology 18 (2021): 2211-2223.

[40] D. V. Krysko, A. D. Garg, A. Kaczmarek, O. Krysko, P. Agostinis, and P. Vandenabeele, “Immunogenic Cell Death and DAMPs in Cancer Therapy,” Nature Reviews Cancer 12 (2012): 860-875.

[41] S. D. Jeong, B.-K. Jung, H. M. Ahn, et al., “Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes With PD-L1 Immune Checkpoint Blockade,” Advanced Science 8 (2021): 2001308.

[42] A. Del Prete, V. Salvi, A. Soriani, et al., “Dendritic Cell Subsets in Cancer Immunity and Tumor Antigen Sensing,” Cellular & Molecular Immunology 20 (2023): 432-447.

[43] A. Christofides, L. Strauss, A. Yeo, C. Cao, A. Charest, and V. A. Boussiotis, “The Complex Role of Tumor-Infiltrating Macrophages,” Nature Immunology 23 (2022): 1148-1156.

[44] M. I. Cybulsky, C. Cheong, and C. S. Robbins, “Macrophages and Dendritic Cells,” Circulation Research 118 (2016): 637-652.

[45] J. Liu, X. Zhang, Y. Cheng, and X. Cao, “Dendritic Cell Migration in Inflammation and Immunity,” Cellular & Molecular Immunology 18 (2021): 2461-2471.

[46] T. R. Mempel, J. K. Lill, and L. M. Altenburger, “How Chemokines Organize the Tumour Microenvironment,” Nature Reviews Cancer 24 (2024): 28-50.

[47] A. Alcorta, L. Lopez-Gomez, R. Capasso, and R. Abalo, “Vitamins and Fatty Acids Against Chemotherapy-Induced Intestinal Mucositis,” Pharmacology & Therapeutics 261 (2024): 108689.

[48] Y. Gao, W. Li, J. Chen, et al., “Pharmacometabolomic Prediction of Individual Differences of Gastrointestinal Toxicity Complicating Myelosuppression in Rats Induced by Irinotecan,” Acta Pharmaceutica Sinica B 9 (2019): 157-166.

[49] R. M. England, J. I. Hare, J. Barnes, et al., “Tumour Regression and Improved Gastrointestinal Tolerability From Controlled Release of SN-38 From Novel Polyoxazoline-Modified Dendrimers,” Journal of Controlled Release 247 (2017): 73-85.

[50] J. Meng, Y. F. Abu, Y. Zhang, et al., “Opioid-Induced Microbial Dysbiosis Disrupts Irinotecan (CPT-11) Metabolism and Increases Gastrointestinal Toxicity in a Murine Model,” British Journal of Pharmacology 180 (2023): 1362-1378.

[51] G. Gao, X. Sun, and G. Liang, “Nanoagent-Promoted Mild-Temperature Photothermal Therapy for Cancer Treatment,” Advanced Functional Materials 31 (2021): 2100738.

[52] F. McNab, K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra, “Type I Interferons in Infectious Disease,” Nature Reviews Immunology 15 (2015): 87-103.

[53] H. Zhang, J. Gao, Y. Tang, T. Jin, and J. Tao, “Inflammasomes Cross-Talk With Lymphocytes to Connect the Innate and Adaptive Immune Response,” Journal of Advanced Research 54 (2023): 181-193.

[54] J. Crouse, U. Kalinke, and A. Oxenius, “Regulation of Antiviral T Cell Responses by Type I Interferons,” Nature Reviews Immunology 15 (2015): 231-242.

[55] L. Zhou, Y. Zhang, Y. Wang, et al., “A Dual Role of Type I Interferons in Antitumor Immunity,” Advanced Biosystems 4 (2020): 1900237.

[56] X. Jiang, J. Wang, X. Deng, et al., “Role of the Tumor Microenvironment in PD-L1/PD-1-Mediated Tumor Immune Escape,” Molecular Cancer 18 (2019): 10.

[57] C. Cui, J. Wang, E. Fagerberg, et al., “Neoantigen-Driven B Cell and CD4 T Follicular Helper Cell Collaboration Promotes Anti-Tumor CD8 T Cell Responses,” Cell 184 (2021): 6101-6118.e13.

[58] P. S. Hegde and D. S. Chen, “Top 10 Challenges in Cancer Immunotherapy,” Immunity 52 (2020): 17-35.

RIGHTS & PERMISSIONS

2025 The Author(s). Aggregate published by SCUT, AIEI, and John Wiley & Sons Australia, Ltd.